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Abstract
Background: The patent ductus arteriosus (PDA) is an important problem in premature infants.
Surgical PDA ligation is usually only be considered when medical treatment has either failed or was
contraindicated. The aims of our study were to determine the mortality and morbidity following
patent ductus arteriosus ligation in premature infants, and whether prostaglandin synthetase
inhibitor (PSI) use prior to ligation affects outcome.
Methods: A retrospective case note review study to determine the outcome of premature infants
undergoing patent ductus arteriosus ligation in one tertiary neonatal intensive care unit and two
paediatric cardiothoracic centres.
Results: We had follow-up data on 87 infants. Cumulative mortality rates at 7 days, 30 days and
at hospital discharge were 2%, 8% and 20% respectively. The incidence of chronic lung disease,
intraventricular haemorrhage, necrotising enterocolitis and retinopathy of prematurity were 77%,
39%, 26% and 28% respectively. There was no difference in mortality, incidence of chronic lung
disease or duration of oxygen dependence between those who had and those who had not
received a PSI prior to surgical ligation. In those who had received 2 or more courses of PSI prior
to surgical ligation, there was a trend to increase in the duration of oxygen therapy and chronic
lung disease, but no difference in mortality.
Conclusion: This study shows that patent ductus arteriosus ligation is a relatively safe procedure
(30 day survival 92%) but there is substantial late mortality and a high incidence of morbidity in the
survivors. 2 or more courses of PSI prior to surgical ligation trends to increased oxygen
dependence and chronic lung disease. This high risk population requires careful follow-up. A
definitive prospective cohort study is lacking.
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Background
The patent ductus arteriosus (PDA) is an important prob-
lem in premature infants [1]. Left to right shunting
through the PDA results in increased pulmonary blood
flow and steal from the systemic circulation. These
haemodynamic changes may be responsible for the co-
morbid conditions associated with a PDA: prolonged ven-
tilator dependence and chronic lung disease (CLD) [2],
pulmonary haemorrhage (PH) [3], intraventricular haem-
orrhage (IVH) [4], necrotising enterocolitis (NEC) [5] and
retinopathy of prematurity (ROP) [6]. Neonatologists
may use a variety of first line strategies to close a PDA in a
symptomatic preterm infant, including careful fluid
administration, diuretics and prostaglandin synthetase
inhibitors (PSI) such as Indomethacin or Ibuprofen. Sur-
gical PDA ligation would usually only be considered
when medical treatment had either failed or was contrain-
dicated.
The primary aim of this study was to determine mortality
after surgical PDA ligation in three centres in the United
Kingdom. Secondary aims were (1) to determine the rela-
tionship between prior use of PSI on the timing of surgical
ligation, duration of oxygen dependency, chronic lung
disease and mortality and (2) to describe the incidence of
CLD, IVH, NEC and ROP in this neonatal population.
Methods
Infants who underwent surgical PDA ligation were identi-
fied from databases held at three hospitals. Centre A the
Neonatal Intensive Care Unit (NICU) Addenbrooke's
Hospital, Cambridge (1995–2000), Centre B the Depart-
ment of Paediatric Cardiology, Guy's and St Thomas' Hos-
pitals, London (1995–1999) and Centre C the
Department of Paediatric Cardiology, Great Ormond
Street Hospital, London (1999–2000). Infants were
excluded if they were greater than 35 weeks gestation at
birth, had other congenital heart disease requiring surgery
or had been discharged home from the neonatal unit
before surgical ligation was performed.
A retrospective case note review was performed. At the
time of the study, ethics committee approval was not
required. Permission to access the notes was granted by
the Research and Development Department at Great
Ormond Street Hospital, the Audit Lead at Guy's and St
Thomas' Hospital and the Audit Department at Adden-
brooke's Hospital. Pre-operative details collected
included birth gestation, birth weight, and use of prostag-
landin synthetase inhibitors. Operative details included
age and weight at ligation. Paediatricians referring infants
to centres B and C were contacted to provide follow-up
information on infants discharged from the cardiotho-
racic centres. Postoperative details recorded were out-
come, age and cause of death, duration of ventilation and
total number of days of oxygen dependency. The presence
of CLD (defined as oxygen dependency at 36 weeks cor-
rected gestational age), IVH, NEC and ROP was also
recorded. Statistical analysis of data was performed using
the Kruskal Wallis test, the Mann Whitney U test, and
Fishers exact test. Approximate 95% intervals for non-par-
ametric data were obtained.
Results
98 patients were identified from the three databases: 21
from centre A, 42 from centre B and 35 from centre C. Fol-
low up data was available from 21/21 from Centre A, 35/
42 from Centre B and 31/35 from Centre C. For the whole
cohort, pre-operative data, duration of oxygen depend-
ency, incidence of CLD, NEC, and IVH was available for
84 (86%) patients. Outcome survival data with informa-
tion on the age and cause of death was available in
87(89%) patients. Details of PSI use were available for 82
(84%) and incidence of ROP was recorded in 79 (81%)
patients.
Demographic details
Demographic details of the infants undergoing surgical
PDA ligation are shown in Table 1. There were no signifi-
cant differences in birth gestation, birth weight or opera-
tion weight between the three centres. Surgical ligation
tended to be performed later in centre B than in centres A
and C (p = 0.05).
Mortality following PDA ligation
There were 17 deaths among the 87 patients where out-
come data was available. The causes and ages of the death
are shown in Table 4. The median age of death after sur-
Table 1: Patient demographics of infants undergoing PDA ligation in the 3 centres – Centre A – Cambridge, Centre B – Guys and St 
Thomas, Centre C – Great Ormond Street. Results are expressed as median (95% confidence interval).
Demographic Centre A n = 21 Centre B n = 35 Centre C n = 28 p value*
Birth weight (grams) Median (95% CI) 820 (649–1020) 770 (710–840) 807 (728–980) 0.67
Birth gestation (weeks) Median (95% CI) 27 (24–28) 25 (25–26) 26 (25–27) 0.32
Ligation weight (grams) Median (95% CI) 963 (781–1169) 1050 (910–1170) 950 (795–1100) 0.66
Ligation age (days) Median (95% CI) 23 (20–31) 31 (25–41) 27 (21–30) 0.05
*Kruskall Wallis testBMC Pediatrics 2006, 6:15 http://www.biomedcentral.com/1471-2431/6/15
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gery was 31 (range 6 – 134) days. For the whole cohort,
postoperative mortality was 2% at 7 days, 8% at 30 days
and 20% beyond day 30 up to hospital discharge. 30 day
mortality was 1/21 (5%), 4/35 (11%), and 2/31 (6%)
from Centres A, B and C respectively. Survival to hospital
discharge was 72% in centre A, 83% in centre B and 84%
in centre C. However no long term outcome data was
available for 7 infants from centre B and 4 infants from
centre C. Only one death was directly attributed to surgery
performed in a cardiothoracic centre. This infant under-
went a second thoracotomy to treat a persisting chylotho-
rax. During this procedure the aorta was damaged and the
infant subsequently died from renal failure. Ten of the
deaths resulted from respiratory complications: CLD (3);
pulmonary interstitial emphysema (PIE) (4); Cor pulmo-
nale (2) and bronchiolitis (1).
The use and effect of prostaglandin synthetase inhibitors 
on ligation and morbidity
Sixty-five of 82 babies were treated with PSI prior to sur-
gery. 28 infants received one course, 33 received two or
more courses and 4 infants received PSI but exact treat-
ment details were unavailable. Seventeen infants were not
treated with PSI for the following reasons: renal failure
(4), pre-existing NEC (4), PH (1), thrombocytopaenia
(1), deemed too old (4) and not specified (3). The median
age at operation of 24 (95% CI 21–27) days after one
course of PSI, was significantly lower than the age at oper-
ation after two or more courses of 31 (95% CI 25–44)
days (p = 0.004). Although there was no statistical signif-
icance, the 95% confidence intervals showed a clinically
relevant increase in duration of oxygen requirement after
2 or more courses of PSI. There was similarly a clinically
important trend to increasing chronic lung disease
although the p value was not significant. There was no dif-
ference in mortality when ligation occurred after single or
multiple courses of PSI Table (2).
Comparison between the group of infants who did not
receive any PSI prior to ligation with those who did
receive a PSI, showed no significant effect on duration of
oxygen dependency, the incidence of CLD or mortality
Table (3).
Morbidity following PDA ligation
Morbidity outcome data was available for up to 84
infants. The incidence of chronic lung disease was 77%
(65/84), intraventricular haemorrhage 39% (33/84),
necrotising enterocolitis 26% (22/84) and of retinopathy
of prematurity 28% (22/79).
Discussion
The results from this three centre study show high survival
rates of 98% and 92% at 7 and 30 days respectively fol-
lowing surgical PDA ligation. These rates are similar to
previous studies that have shown that PDA ligation is a
relatively safe procedure [7,8], whether it is done on a
NICU [9] or after transfer to a cardio-thoracic centre [10].
In the NICU (centre A) the procedure was performed by
one of two consultant adult cardio-thoracic surgeons
trained in PDA ligation. In the paediatric cardiothoracic
centres B and C the ligations were carried out by specialist
registrars and consultant paediatric cardiothoracic sur-
geons. Where local expertise is available, the advantages
of performing PDA ligation on NICU include: minimal
disturbance of the infant; no requirement for transporta-
Table 2: Comparing the outcome of PDA ligation after 1 or more courses of prostaglandin synthetase inhibitors
Parameter Ligation after 1 course of PSI (n = 28) Ligation after >1 course of PSI (n = 33) p value
Age at operation. Median (95% CI) 24 (21–27) days 31 (25–44) days 0.004*
Total days in oxygen. Median (95% CI) 85.5 (58–120) 119 (89–175) 0.09*
Incidence of CLD 19 (68%) 28 (85%) 0.14¥
Deaths 7 (25%) 8 (24%) 1.0¥
*Mann Whitney U test
¥Fisher exact test
Table 3: Comparison of the outcome of PDA ligation with and without previous prostaglandin synthetase inhibitor
Parameter PDA ligation without previous PSI (n = 17) PDA ligation after PSI (n = 65) p value
Total days in oxygen Median (95% CI) 83 (48–142) days 102 (78–126) days 0.20*
Incidence of CLD 13 (76%) 50 (77%) 1.00¥
Deaths 2 (12%) 15 (23%) 0.50¥
* Mann Whitney U test
¥Fisher exact testBMC Pediatrics 2006, 6:15 http://www.biomedcentral.com/1471-2431/6/15
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tion; no separation from parents and easier scheduling of
the procedure.
The short-term outcome following PDA ligation was
excellent, but there was a further 12% mortality between
30 days and hospital discharge. We feel that this late mor-
tality was not due to the surgery itself but rather repre-
sented that fact that this population was already at high
risk of morbidity and mortality, which was then com-
pounded by a PDA. Respiratory complications accounted
for the majority of infant deaths in this study, which is not
unexpected given the overall incidence of CLD of 77%.
The analysis of the data on late mortality is limited by the
lack of follow up data from the cardiothoracic centres.
This is a disadvantage of a retrospective study. We are una-
ble to estimate the effect of this loss of follow up on our
results. The results from centre A, for whom we have
100% follow-up, give a 72% survival to hospital discharge
which may suggest that we are overestimating survival. We
acknowledge the potential effect of the missing data on
our results, but feel that the high late mortality we have
found is important.
The ideal treatment of the PDA is subject to much debate
[11]. In the United Kingdom surgical treatment is usually
considered after failure or contraindication of medical
treatment. Early surgical closure of a PDA without prior
indomethacin treatment has not been shown to improve
survival [12]. Similarly there is no significant effect on
incidence of chronic lung disease, neurodevelopmental
outcome or mortality between prophylactic or selective
administration of indomethacin [13]. In our study popu-
lation there was a great variation in practice regarding the
use of PSI and the timing of surgical ligation. Our num-
bers were small and so we have given approximate 95%
confidence intervals as well as p values to give a clearer
picture. Although there was no difference in morbidity
and mortality between the groups who had or had not
received a PSI, on further analysis of the group who had
received a PSI, it was apparent that there was a delayed
operation and increasing respiratory morbidity if 2 or
more courses of PSI were given. The increased respiratory
morbidity may be an effect of the prolonged left to right
shunting on the pulmonary vasculature and pulmonary
function.
There are circumstances where the PDA is protective to the
lungs – for example in the case of pulmonary hyperten-
sion. In this situation, the appropriateness of PDA ligation
is dependent on the echocardiographic assessment. Our
discussion of the timing of PDA ligation is limited by not
having details of the echocardiographic assessments at the
referring hospital. The definition of a significant PDA is
however also controversial and echocardiographic and
clinical criteria for diagnosis of a significant PDA vary
between units.
There were not enough subjects in our study to analyse the
effects of birth gestational age or birth weight on outcome.
Further work would be useful since the PDA is most prev-
alent in extremely premature and very low birth weight
infants [14,15]. In this group medical treatment with
indomethacin has been shown to be less effective and
may be associated with complications [16]. Earlier consid-
eration of surgical ligation in these infants may be appro-
priate; PDA ligation has been demonstrated to be safe [17]
and there was a significant decrease in the incidence of
NEC in a study comparing prophylactic surgery with
indomethacin treatment in neonates with birth weight
less than 1000 g [18].
This retrospective study provides useful data on outcomes
and the incidence of complications in premature infants
undergoing PDA ligation. However, there are some limi-
tations. Firstly, the study periods in the three units were
not identical, but overlap. Secondly, follow-up of infants
proved difficult and full information was only available
for 86% of the identified cohort. Neonatal unit follow-up
has been well established for some time and a complete
dataset was available for infants undergoing operations
on NICU. The long term follow of patients undergoing
cardiothoracic procedures remains in its infancy. PDA
ligation was not considered a benchmark procedure in the
analysis of the central cardiac audit database (CCAD)
[19]. PDA ligation is regarded as a straightforward proce-
dure that does not require cardiac bypass. In our popula-
tion however mortality is high when compared to other
non-bypass procedures.
This study is also limited as we had no controls to com-
pare associated morbidities, especially the neurodevelop-
mental outcomes. We can therefore only make
comparisons with previously published work. Recent
studies in neonatal intensive care demonstrate a lower
incidence of CLD than found in this study group, varying
Table 4: Cause of death and postoperative day of death following 
PDA ligation
Cause of Death Postoperative 
days to death
Respiratory Chronic lung disease 76, 100, 134
Pulmonary interstitial emphysema 6, 7, 13, 17
RSV bronchiolitis and CLD 31
Cor pulmonale secondary to CLD 45, 47
Aspiration 67
Renal Failure 50, 56
Sepsis 9,22
Sudden infant death 47
Unknown 22BMC Pediatrics 2006, 6:15 http://www.biomedcentral.com/1471-2431/6/15
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from 29% in infants under 32 week gestation [20] to 68%
in 23–28 week gestation infants [21]. The incidence of
NEC in this cohort was higher than published figures of
between 6–9% in those of gestational age 29 weeks or less
[22] and 9–13% in those < 34weeks and < 1500 g at birth
[23]. Comparative figures for IVH and ROP are less useful
due to differences in classification, but a large study of
infants with gestational age 25 weeks or less reports inci-
dences of up to 16% for grade 3 IVH and above and of up
to 55% for grade 3 or worse ROP [24]. The vast majority
of infants in these studies [20-24] will not have required
surgical closure of PDA. The high incidence of CLD, NEC,
IVH and ROP in this series illustrates that this population
represents one of the sickest group of infants in NICU
who often require prolonged ventilation.
In summary, we feel that the long term mortality of up to
20% and the associated morbidity cannot be ignored. We
would recommend that paediatricians and cardiologists
consider a collaborative nationwide prospective study to
look at the relationship between timing of ductal ligation
and outcome in this neonatal population. Such studies
should not be restricted to 30 day or 12 month survival as
in the CCAD analysis. Longer term follow-up will be nec-
essary to identify the later deaths and associated morbid-
ity including neurodevelopmental outcome.
Conclusion
This study shows that patent ductus arteriosus ligation is
a relatively safe procedure (30 day survival 92%) but there
is substantial late mortality and a high incidence of mor-
bidity in the survivors. 2 or more courses of PSI prior to
surgical ligation trends to increased oxygen dependence
and chronic lung disease. This high risk population
requires careful, long term follow-up. A definitive pro-
spective cohort study is lacking.
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